Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Measurement: Standard Units
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
Standard Enthalpy of Formation
Standard Electrode Potentials
您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Updated: Feb 14, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Victoria E J M Palasantzas1,2, Dicky Struik1, Trijnie Bos1
1Department of Pediatrics, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
大多数营养品,包括短链脂肪酸 (SCFA) 和抗氧化剂 (AOX),在标准化体外模型中没有减少肝脂肪. 维生素E是一个例外,而一些化合物意外增加了甘油三,强调了对代谢相关脂肪性肝病 (MASLD) 治疗的严格测试的需要.
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: